Q32 Bio定价2亿美元股权融资

• Q32 Bio (QTTB) priced an underwritten public offering expected to raise approximately $200M in gross proceeds.
• The clinical-stage biotechnology company is offering 6.03M shares of common stock at $18.25 per share and, in lieu of common stock for certain investors, pre-funded warrants to purchase 4.93M shares at $18.2499 each.
• The proceeds estimate assumes no exercise of the underwriters' 30-day option to purchase up to an additional 1.64M shares.
• The offering is expected to close on July 16.
• Net proceeds will be used for working capital, including research, clinical development and commercialization activities, with a focus on advancing bempikibart into future clinical trials.
• The stock price increased about 2.6% on Tuesday during after market hours of trading.

More on Q32 Bio

• Q32 Bio: 'Strong Buy' On Solid Bempikibart SIGNAL-AA Study Data And Catalysts
• Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts
• Q32 Bio announces $200M offering of common stock and pre-funded warrants
• Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
• Seeking Alpha’s Quant Rating on Q32 Bio